That's what Eli Lilly did. It ran a phase 3b trial where some patients living with obesity were given tirzepatide (the active ingredient in Zepbound) while others received semaglutide (the active ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business ...

Wall Street analysts who follow Viking and Summit expect further gains in 2025. Quick gains are often lost on Wall Street, ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial.

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

Obesity is one of the greatest public health issues facing the NHS and weight loss drugs, such as tirzepatide, are an important tool in helping people lose weight while also reducing the risk of other ...

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...